What is HC Wainwright’s Estimate for Genmab A/S Q4 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Stock analysts at HC Wainwright issued their Q4 2027 EPS estimates for shares of Genmab A/S in a research report issued to clients and investors on Monday, October 19th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of $0.61 for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.20 per share.

Other analysts have also recently issued research reports about the company. Truist Financial raised their price target on Genmab A/S from $40.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Morgan Stanley set a $42.00 price objective on Genmab A/S in a report on Tuesday. Guggenheim upped their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Finally, TD Cowen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their target price for the company from $32.00 to $43.00 in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.39.

Genmab A/S Price Performance

Genmab A/S stock opened at $38.50 on Tuesday. Genmab A/S has a 52 week low of $23.62 and a 52 week high of $40.17. The business has a 50-day simple moving average of $34.51 and a 200 day simple moving average of $29.86. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The stock has a market cap of $24.03 billion, a price-to-earnings ratio of 26.62, a PEG ratio of 1.73 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently added to or reduced their stakes in the company. Capital Square LLC purchased a new stake in shares of Genmab A/S in the 3rd quarter valued at $219,000. Frank Rimerman Advisors LLC bought a new position in shares of Genmab A/S during the 3rd quarter valued at $244,000. Terra Nova Asset Management LLC raised its position in Genmab A/S by 6.7% in the 3rd quarter. Terra Nova Asset Management LLC now owns 68,527 shares of the company’s stock worth $2,445,000 after purchasing an additional 4,288 shares during the period. GAMMA Investing LLC raised its position in Genmab A/S by 20.5% in the 3rd quarter. GAMMA Investing LLC now owns 4,792 shares of the company’s stock worth $171,000 after purchasing an additional 814 shares during the period. Finally, Juncture Wealth Strategies LLC lifted its stake in Genmab A/S by 42.0% in the third quarter. Juncture Wealth Strategies LLC now owns 10,424 shares of the company’s stock worth $372,000 after purchasing an additional 3,083 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.